InsiderTrades

Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2022-11-17 00:00:00 ET · period of report 2022-11-15 · accession 0001787306-22-000075 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-11-17 2022-11-15 ARQT Welgus Howard G. Dir S - Sale+OE $20.01 -3,403 165.8K -2% -$68.1K
D 2022-11-17 2022-11-15 ARQT Welgus Howard G. Dir M - OptEx $1.68 +1,020 169.2K +0.6% +$1,714
D 2022-11-17 2022-11-15 ARQT Welgus Howard G. Dir M - OptEx $0.00 -1,020 40.5K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-11-15 S D 3,403 $20.01 165,825 D — — (F3) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
2 Common Common Stock 2022-11-15 M A 1,020 $1.68 169,228 D — — (F2) Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
3 Derivative Stock Option (right to buy) 2022-11-15 M D 1,020 $0.00 40,458 D $1.68 · — to 2029-03-13 1,020 Common Stock (F5) The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.